DNLI

Denali Therapeutics Inc.

DNLI · CIK 1714899 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0M
20182025
Net Income−$513M
20182025
Operating CF−$413M
20182025
Free Cash Flow−$422M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.3B$0.1B$0.0B$0.3B$0.0B$0.1B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.4B$0.4B$0.4B$0.4B$0.3B$0.2B$0.2B$0.1B
SG&A Expense————————
Operating Income$-0.6B$-0.5B$-0.2B$-0.3B$-0.3B$0.1B$-0.1B$0.1B
Net Income$-0.5B$-0.4B$-0.1B$-0.3B$-0.3B$0.1B$-0.1B$0.1B
EPS (Basic)$-2.97$-2.57$-1.06$-2.60$-2.39$0.65$0.82$0.82
EPS (Diluted)$-2.97$-2.57$-1.06$-2.60$-2.39$0.63$0.79$0.79

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.1B$1.4B$1.2B$1.5B$1.4B$1.6B$0.6B$0.7B
Current Assets$0.9B$0.9B$1.1B$1.4B$0.9B$1.5B$0.4B$0.5B
Cash & Equivalents$0.2B$0.2B$0.1B$0.2B$0.3B$0.5B$0.1B$0.1B
Total Liabilities$0.1B$0.1B$0.1B$0.4B$0.4B$0.5B$0.2B$0.1B
Current Liabilities$0.1B$0.1B$0.1B$0.4B$0.4B$0.1B$0.0B$0.0B
Stockholders' Equity$1.0B$1.2B$1.0B$1.0B$1.0B$1.2B$0.4B$0.5B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.4B$-0.3B$-0.4B$-0.2B$-0.2B$0.4B$-0.2B$0.1B
Investing Cash Flow$0.3B$-0.1B$0.2B$-0.1B$-0.0B$-0.6B$0.1B$-0.3B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.5B$0.0B$0.3B$0.0B$0.6B$0.0B$0.1B
← Companies